Expert Recap

Update on Investigational Antiretrovirals

Source: Investigational Antiretrovirals*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on Investigational Antiretrovirals

Faculty:
Joseph J. Eron, Jr., MD

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.8 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of the CCR5 antagonists maraviroc and vicriviroc in treatment-naive and treatment-experienced HIV-infected patients
Summarize the safety and efficacy of the investigational integrase inhibitor raltegravir in treatment-naive HIV-infected patients
Recount recent findings from studies of the investigational NNRTIs rilpivirine and etravirine in treatment-naive and treatment-experienced HIV-infected patients

CCO Expert Recaps combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.